Royalty Pharma Plc
A buyer of biopharmaceutical royalties: it pays universities, hospitals, foundations, and drugmakers upfront cash in exchange for a share of future sales of approved and late-stage medicines like Vertex's Trikafta cystic fibrosis treatment and Xtandi. Founded in 1996 by former Lazard banker Pablo Legorreta, who got the idea after watching a chemotherapy royalty investment pay off, it grew into one of the world's largest acquirers of drug royalty streams. Notably, it never develops drugs itself—it simply collects a slice of the top-line sales of treatments others make and sell.
Sold 828.3K
Sold 1.50M
Bought 3.00M · Sold 7.30M
Sold 732.2K
Bought 50.0K
Sold 1.00M
Granted 648.5K · Bought 600.0K
Granted 7.7K
Granted 6.6K · Bought 1.50M
Sold 886.6K
Granted 58.5K · Bought 14.2K · Sold 2.09M
Sold 908.9K
Granted 109.4K · Bought 70.0K · Sold 150.0K
Granted 7.7K · Sold 5.67M
Granted 82.0K · Sold 422.6K
Granted 85.9K · Sold 36.5K
Granted 65.5K · Bought 58.2K
Granted 81.4K
Granted 79.2K
Granted 109.4K · Sold 1.31M
Granted 48.5K
Granted 54.7K
Granted 37.9K
Granted 15.3K
Granted 13.1K
Granted 13.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Avara Management Ltd +2 co-filers10% owner, Director, 10% owner · 6 transactions | — | 96.98Mas of Dec 2022 | — | — | 828.3K |
| GG 1978 Sicaf Sif S.A. +1 co-filer10% owner · 8 transactions | — | 88.47Mas of Sep 2022 | — | — | 1.50M |
| Atchinson Robert +4 co-filers10% owner · 4 transactions | — | 38.71Mas of Dec 2020 | — | 3.00M | 7.30M |
| Giuliani Mario Germano +2 co-filersDirector, 10% owner, 10% owner · 4 transactions | — | 38.63Mas of Sep 2022 | — | — | 732.2K |
| Avara Management Ltd +4 co-filers10% owner, Director, 10% owner · 5 transactions | — | 35.99Mas of Jun 2020 | — | 50.0K | — |
| Avara Management Ltd +1 co-filerDirector, 10% owner, 10% owner · 6 transactions | — | 30.08Mas of Jan 2024 | — | — | 1.00M |
| Legorreta Pablo G.CEO, Chairman of the Board, Director · 20 transactions | — | 27.90M | 648.5K | 600.0K | — |
| Giuliani Mario GermanoDirector, 10% owner · 1 transaction | — | 7.80Mas of Jun 2023 | 7.7K | — | — |
| Ford William EDirector · 5 transactions | — | 4.09Mas of Jun 2021 | 6.6K | 1.50M | — |
| Avara Management Ltd +4 co-filers10% owner, Director, 10% owner · 5 transactions | — | 3.53Mas of Dec 2022 | — | — | 886.6K |
| Lloyd George W.EVP, Investments & CLO · 92 transactions | — | 2.74M | 58.5K | 14.2K | 2.09M |
| Reddoch James F.EVP & Chief Scientific Officer · 26 transactions | — | 845.8Kas of Sep 2022 | — | — | 908.9K |
| Hite ChristopherEVP & Chairman, Partnering · 10 transactions | — | 747.0K | 109.4K | 70.0K | 150.0K |
| Riggs Rory BDirector · 72 transactions | — | 420.3Kas of Feb 2024 | 7.7K | — | 5.67M |
| Urist MarshallEVP, Research & Investments · 34 transactions | — | 278.7K | 82.0K | — | 422.6K |
| Norden GregoryDirector · 11 transactions | — | 196.3K | 85.9K | — | 36.5K |
| Fernandez Henry ADirector · 28 transactions | — | 123.5Kas of Jun 2025 | 65.5K | 58.2K | — |
| Desouza Errol BDirector · 7 transactions | — | 81.4Kas of May 2025 | 81.4K | — | — |
| Bassler Bonnie LDirector · 32 transactions | — | 79.2K | 79.2K | — | — |
| Coyne Terrance P.EVP & CFO · 55 transactions | — | 76.7K | 109.4K | — | 1.31M |
| Love Ted WDirector · 7 transactions | — | 58.4K | 48.5K | — | — |
| Engelbert Catherine M.Director · 8 transactions | — | 55.7K | 54.7K | — | — |
| Hodgson David CDirector · 6 transactions | — | 37.9K | 37.9K | — | — |
| Coric VladDirector · 3 transactions | — | 15.3K | 15.3K | — | — |
| Ho CaroleDirector · 3 transactions | — | 13.1K | 13.1K | — | — |
| Weatherman Elizabeth HDirector · 3 transactions | — | 13.1K | 13.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -17.54M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.